127 related articles for article (PubMed ID: 16219580)
1. Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma.
van Agthoven M; Kramer MH; Sonneveld P; van der Hem KG; Huijgens PC; Wijermans PW; Kluin-Nelemans HC; Schaafsma MR; Biesma DH; Mattijssen V; Uyl-de Groot CA; Hagenbeek A
Haematologica; 2005 Oct; 90(10):1422-32. PubMed ID: 16219580
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
[TBL] [Abstract][Full Text] [Related]
3. Cost determinants in aggressive non-Hodgkin's lymphoma.
van Agthoven M; Sonneveld P; Verdonck LF; Uyl-de Groot CA
Haematologica; 2005 May; 90(5):661-71. PubMed ID: 15921381
[TBL] [Abstract][Full Text] [Related]
4. [Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal].
Braga P; Carvalho S; Gomes M; Guerra L; Lúcio P; Marques H; Negreiro F; Pereira C; Silva C; Teixeira A
Acta Med Port; 2010; 23(6):1025-34. PubMed ID: 21627880
[TBL] [Abstract][Full Text] [Related]
5. The cost of treating relapsed indolent non-Hodgkin's lymphoma in an international setting: retrospective analysis of resource use.
Herold M; Sacchi S; Hieke K
Haematologica; 2002 Jul; 87(7):719-29; discussion 729. PubMed ID: 12091123
[TBL] [Abstract][Full Text] [Related]
6. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
[TBL] [Abstract][Full Text] [Related]
7. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients.
Woronoff-Lemsi MC; Arveux P; Limat S; Deconinck E; Morel P; Cahn JY
Bone Marrow Transplant; 1997 Dec; 20(11):975-82. PubMed ID: 9422478
[TBL] [Abstract][Full Text] [Related]
8. [Bottom-up analysis of the case costs of stem cell transplantation and selected chemotherapies].
Stäbler W; Wagner B
Klin Padiatr; 2003; 215(3):179-84. PubMed ID: 12778360
[TBL] [Abstract][Full Text] [Related]
9. Costs of treating bleeding and perforated peptic ulcers in The Netherlands.
de Leest H; van Dieten H; van Tulder M; Lems WF; Dijkmans BA; Boers M
J Rheumatol; 2004 Apr; 31(4):788-91. PubMed ID: 15088309
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
11. Costs and quality of life in multiple sclerosis in The Netherlands.
Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
[TBL] [Abstract][Full Text] [Related]
12. The incremental cost effectiveness of in-patient versus out-patient rehabilitation after total hip arthroplasty - results of a pilot investigation.
Krummenauer F; Günther KP; Witzlebf WC
Eur J Med Res; 2008 Jun; 13(6):267-74. PubMed ID: 18558552
[TBL] [Abstract][Full Text] [Related]
13. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity analysis of cost factors for various therapy options in the treatment of follicular lymphoma.
Schmitz S; Aly F; Steinmetz T; Diehl V; Rehwald U
Onkologie; 2006 Jun; 29(6):258-64. PubMed ID: 16770087
[TBL] [Abstract][Full Text] [Related]
15. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.
Al-Tourah AJ; Gill KK; Chhanabhai M; Hoskins PJ; Klasa RJ; Savage KJ; Sehn LH; Shenkier TN; Gascoyne RD; Connors JM
J Clin Oncol; 2008 Nov; 26(32):5165-9. PubMed ID: 18838711
[TBL] [Abstract][Full Text] [Related]
16. Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.
Ihbe-Heffinger A; Paessens BJ; von Schilling C; Shlaen M; Gottschalk N; Berger K; Bernard R; Kiechle M; Peschel C; Jacobs VR
Onkologie; 2011; 34(5):241-6. PubMed ID: 21577029
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry.
Ong AT; Daemen J; van Hout BA; Lemos PA; Bosch JL; van Domburg RT; Serruys PW
Eur Heart J; 2006 Dec; 27(24):2996-3003. PubMed ID: 17114234
[TBL] [Abstract][Full Text] [Related]
18. Assessing short-term effects and costs at an early stage of innovation: the use of positron emission tomography on radiotherapy treatment decision making.
Remonnay R; Morelle M; Pommier P; Giammarile F; Carrère MO
Int J Technol Assess Health Care; 2008; 24(2):212-20. PubMed ID: 18400125
[TBL] [Abstract][Full Text] [Related]
19. [The role of cost analysis in the evaluation of the development of medical technology. The case of allogenic stem-cell transplantation].
Groot MT; van Agthoven M; Löwenberg B; Willemze R; Uyl-de Groot CA
Ned Tijdschr Geneeskd; 2004 Mar; 148(10):480-4. PubMed ID: 15042895
[TBL] [Abstract][Full Text] [Related]
20. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E
Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
